Market Cap 117.84M
Revenue (ttm) 10.66M
Net Income (ttm) -63.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -596.25%
Debt to Equity Ratio 0.00
Volume 6,300
Avg Vol 20,230
Day's Range N/A - N/A
Shares Out 8.57M
Stochastic %K 48%
Beta 0.63
Analysts Strong Sell
Price Target $37.00

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat di...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 489 9000
Address:
171 Oyster Point Boulevard, Suite 400, South San Francisco, United States
Jessikah__Liu
Jessikah__Liu Oct. 25 at 7:55 PM
I like this. $EEIQ is def positioning for something and it could turn up to be the first 100% mover next week. Whatever their plans, it has great volatility and is a safe hold until well into next year. Thanks for bringing my attention to these others. I was watching the $SRZN action but completely missed $GTBP. And that one's a favorite of mine. Have you noticed the slow build $LBGJ has been making lately? That's a hard one to time but when it makes its move it's likely to be legendary.
0 · Reply
Jw242
Jw242 Oct. 22 at 4:04 PM
$SRZN of course the market shart when we get a little mojo
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 20 at 11:54 AM
$SRZN Surrozen was mentioned here:
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 18 at 7:30 AM
$SRZN now we know what's that second drug of Eyebio/Merck. Tiespectus blocks VEGF. So Merck is now developing one WNT drug and one VEGF drug. Not sure what's the difference between Tiespectus and Eylea.
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 17 at 5:54 PM
$SRZN Eyebio/Merck is advertising their drug at the Eyecelerator event which could also help us.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 17 at 4:01 PM
$SRZN yes its over we will be bankrupt soon.
1 · Reply
Jw242
Jw242 Oct. 17 at 4:00 PM
$SRZN it’s over.
0 · Reply
Jw242
Jw242 Oct. 17 at 3:59 PM
$SRZN why won’t they manipulate this up? But always down w the sell walls
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 16 at 8:00 PM
$SRZN why do they need weeks to fill such a position? Are they just trolling or is it a real job? Can't imagine that its hard to find a scientist in San Francisco.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 15 at 5:21 PM
$SRZN i was looking around on LinkedIn and saw that somebody from Abbvie liked a post from our new VP. Then i checked what Abbvie works on or worked on in ophthalmology and i found some interesting things. They got approval for a sustained release implant called Durysta. Because of the side effects it only got approval in the US but not Europe.
1 · Reply
Latest News on SRZN
Surrozen Provides Corporate Update on Clinical Programs

Jan 18, 2024, 8:30 AM EST - 1 year ago

Surrozen Provides Corporate Update on Clinical Programs


Surrozen Provides Third Quarter 2023 Financial Results

Nov 8, 2023, 4:05 PM EST - 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results


Surrozen Provides Second Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides Second Quarter 2023 Financial Results


Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Mar 25, 2023, 10:02 AM EDT - 2 years ago

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript


Surrozen Reports Second Quarter 2022 Financial Results

Aug 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Second Quarter 2022 Financial Results


Surrozen Reports First Quarter 2022 Financial Results

May 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports First Quarter 2022 Financial Results


Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 4:00 PM EST - 4 years ago

Surrozen Reports Third Quarter 2021 Financial Results


Jessikah__Liu
Jessikah__Liu Oct. 25 at 7:55 PM
I like this. $EEIQ is def positioning for something and it could turn up to be the first 100% mover next week. Whatever their plans, it has great volatility and is a safe hold until well into next year. Thanks for bringing my attention to these others. I was watching the $SRZN action but completely missed $GTBP. And that one's a favorite of mine. Have you noticed the slow build $LBGJ has been making lately? That's a hard one to time but when it makes its move it's likely to be legendary.
0 · Reply
Jw242
Jw242 Oct. 22 at 4:04 PM
$SRZN of course the market shart when we get a little mojo
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 20 at 11:54 AM
$SRZN Surrozen was mentioned here:
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 18 at 7:30 AM
$SRZN now we know what's that second drug of Eyebio/Merck. Tiespectus blocks VEGF. So Merck is now developing one WNT drug and one VEGF drug. Not sure what's the difference between Tiespectus and Eylea.
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 17 at 5:54 PM
$SRZN Eyebio/Merck is advertising their drug at the Eyecelerator event which could also help us.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 17 at 4:01 PM
$SRZN yes its over we will be bankrupt soon.
1 · Reply
Jw242
Jw242 Oct. 17 at 4:00 PM
$SRZN it’s over.
0 · Reply
Jw242
Jw242 Oct. 17 at 3:59 PM
$SRZN why won’t they manipulate this up? But always down w the sell walls
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 16 at 8:00 PM
$SRZN why do they need weeks to fill such a position? Are they just trolling or is it a real job? Can't imagine that its hard to find a scientist in San Francisco.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 15 at 5:21 PM
$SRZN i was looking around on LinkedIn and saw that somebody from Abbvie liked a post from our new VP. Then i checked what Abbvie works on or worked on in ophthalmology and i found some interesting things. They got approval for a sustained release implant called Durysta. Because of the side effects it only got approval in the US but not Europe.
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 14 at 3:19 PM
$SRZN Eyecelerator conference is this week.
0 · Reply
raticals
raticals Oct. 13 at 4:06 PM
$SRZN this thing is a coiled spring bigtime
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 12 at 11:10 AM
$SRZN nearly impossible that Surrozen will not be acquired in this environment. Thinking about it even Merck could be interested to get more WNT drugs if they see good results in their trials already. They could get our combination drugs and they would destroy any potential competition if they buy the last WNT drug company that's working on eye diseases. https://hubs.li/Q03LHt8V0
1 · Reply
raticals
raticals Oct. 9 at 10:35 PM
$SRZN short interest creeping up again
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 9 at 7:13 PM
$SRZN some questions that i have are what happened to their sweets platform? Did they delete that after the liver drug failure? What are the scientists working on now? The ophthalmology drugs that we have on the pipeline are kinda done regarding preclinical development and will move into the clinic soon so the scientists must be working on something else since they didn't lay them off. Could they be working on the targeted protein degradation technology to make cancer drugs as mentioned in one release by Surrozen? That could be very interesting and that potential value isn't really visible to shareholders.
0 · Reply
raticals
raticals Oct. 9 at 4:01 PM
$SRZN took one for the team sold 10,000 shares at 14 to kickstart things
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 9 at 9:40 AM
$SRZN Merck added another clinical trial in ophthalmology with a drug acquired through the Eyebio acquisition. Not sure what exactly it is but probably another WNT drug.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 8 at 7:45 AM
$SRZN an article about BI and Re-Vana.
1 · Reply
raticals
raticals Oct. 7 at 1:58 PM
$SRZN I would literally never asked for anything in my life again. All I ask, is that the stock does. $SPRB move. It seems like a simple request 😆
1 · Reply
raticals
raticals Oct. 7 at 12:46 AM
$SRZN this gonna pull an $SPRB soon?
1 · Reply
topstockalerts
topstockalerts Oct. 6 at 8:57 PM
After Hours Top Gainers PT2 $OSCX $PASW $BRTX $MGN $SRZN
0 · Reply
W1nTheM4rket
W1nTheM4rket Oct. 6 at 6:46 PM
$SRZN NXXT giving textbook strength. Loving this momentum
0 · Reply